Anthony Insogna is chair of Jones Day's global IP practice and is a leading pharmaceutical and biotechnology patent lawyer as recognized by Chambers
, Legal 500
, and his peers. He has 25 years of experience enforcing and defending patent portfolios for some of the world's most successful pharmaceutical and biotech therapeutics. Anthony's experience includes domestic and foreign litigation, post-grant proceedings including Inter Partes Review (IPR), patent portfolio strategy, oppositions, interferences, invalidation proceedings, and transactions for products including Abraxane , Allegra , Brovana , Clarinex , Clofar , Embospheres , Ethyol , Focalin , Focalin XR , HepaSpheres , Istodax , Kuvan , Lunesta , Nithiodote , Otezla , Pristiq , Pomalyst , Relafen , Revlimid , Rezield , Ritalin LA , Synagis , Thalomid , Tyzeka , Vidaza , Xyrem , Zytiga , and others as well as many product candidates currently in clinical trials. Currently, he is representing Acadia with pimavanserin for CNS disorders, Puma with neratinib for cancer, Sunesis with vosaroxin for leukemia, Celgene with CC-122 for cancer and CC-220 for inflammation, Akebia with AKB-6548 for CKD anemia, and Ambit Biosciences with quizartinib, among others.
In addition to U.S. and foreign patent litigation, Anthony has significant experience with European oppositions and with Chinese, Canadian, and Australian invalidation proceedings. He also has significant experience with the drug approval process under the U.S. FDA laws and more than 25 years of experience with the Hatch-Waxman Act. He regularly advises on IP issues attendant to M&A, transactions, and financing for life sciences companies.
Anthony founded the San Diego Office of Jones Day before becoming the leader of the Jones Day IP practice.
Celgene wins in district court case, invalidating patent asserted against its Thalomid and Revlimid brand cancer drugs
AbbVie successfully defends patents related to HUMIRA against IPR petitions filed by Amgen
Akebia obtains favorable preliminary decision in invalidity proceedings at JPO
Honors & Distinctions
Chambers: Band 1 (2015-2016)
Legal 500 US: recommended lawyer (2011-2016)
Best Lawyers in America: San Diego Patent Law Lawyer of the Year (2015); San Diego Biotechnology Law Lawyer of the Year (2017)
World IP Review: WIPR Leader (2016)
Daily Journal: Top 25 IP Portfolio Managers in California (2009-2014); Top IP Attorneys in California (2015-2016)
California Super Lawyers (2010-2016)
Intellectual Asset Management: IAM Patent 1000 (2014-2016)
Managing Intellectual Property: IP Star (2014-2016)